Completed PHASE1 INTERVENTIONAL NCT00340431

Experimental Vaccine for Plasmodium Falciparum Malaria

Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Plasmodium Falciparum Malaria Vaccines

Interventions MSP1(42)-FVO & MSP1(42)-3D7

Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Jun 9, 2004 Completion: Feb 6, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Plasmodium Falciparum Malaria and Vaccines and is currently completed. National Institute of Allergy and Infectious Diseases (NIAID) leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lenexa, United States